Ryan C Winger
Overview
Explore the profile of Ryan C Winger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kornilov S, Price N, Gelinas R, Acosta J, Brunkow M, Gervasi-Follmar T, et al.
J Neurol Sci
. 2024 Nov;
467:123303.
PMID: 39561535
The study examined changes in the plasma proteome, metabolome, and lipidome of N = 14 patients with relapsing-remitting multiple sclerosis (RRMS) initiating treatment with ocrelizumab, assayed at baseline, 6 months,...
2.
Kister I, Curtin R, Piquet A, Borko T, Pei J, Banbury B, et al.
Ann Clin Transl Neurol
. 2024 May;
11(7):1750-1764.
PMID: 38713096
Objectives: (1) To plot the trajectory of humoral and cellular immune responses to the primary (two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple sclerosis (MS) patients up...
3.
Cross A, Gelfand J, Thebault S, Bennett J, von Budingen H, Cameron B, et al.
JAMA Neurol
. 2024 Mar;
PMID: 38466277
Importance: Biomarkers distinguishing nonrelapsing progressive disease biology from relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an accessible fluid that most closely reflects central nervous system...
4.
Perez-Paramo Y, Dufield D, Veeramachaneni R, Parkhurst E, Harp C, Ramesh A, et al.
Mol Pharmacol
. 2024 Jan;
105(3):121-130.
PMID: 38182433
Multiple sclerosis is an inflammatory and degenerative disease characterized by different clinical courses including relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). A hallmark of patients with multiple...
5.
Zivadinov R, Pei J, Clayton D, Goldman D, Winger R, Cabatingan M, et al.
J Neurol Neurosurg Psychiatry
. 2023 Dec;
95(6):536-543.
PMID: 38071574
Background: Atrophied T2-lesion volume (aT2-LV) is an exploratory imaging marker in multiple sclerosis (MS) reflecting the volume of lesions subsumed into cerebrospinal fluid (CSF). Objective: To investigate the effect of...
6.
Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-Gonzalez J, et al.
Ann Clin Transl Neurol
. 2023 Feb;
10(4):579-588.
PMID: 36811392
Objective: This study aimed to evaluate safety (infusion-related reactions [IRRs]) and patient satisfaction (patient-reported outcomes [PROs]) for at-home ocrelizumab administration for patients with multiple sclerosis (MS). Methods: This open-label study...
7.
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson K, Kakara M, et al.
Proc Natl Acad Sci U S A
. 2023 Jan;
120(3):e2207291120.
PMID: 36634138
A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting deeper depletion of...
8.
Kister I, Curtin R, Pei J, Perdomo K, Bacon T, Voloshyna I, et al.
Ann Clin Transl Neurol
. 2022 Sep;
9(10):1643-1659.
PMID: 36165097
Objective: To compare "hybrid immunity" (prior COVID-19 infection plus vaccination) and post-vaccination immunity to SARS CoV-2 in MS patients on different disease-modifying therapies (DMTs) and to assess the impact of...
9.
Longbrake E, Hua L, Mowry E, Gauthier S, Alvarez E, Cross A, et al.
Mult Scler Relat Disord
. 2022 Aug;
68:104143.
PMID: 36031693
Background: Patients with radiologically isolated syndrome (RIS) exhibit CNS lesions suggestive of multiple sclerosis (MS) in the absence of overt neurological symptoms characteristic of the disease. They may have concurrent...
10.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, et al.
Ann Neurol
. 2022 Mar;
91(6):782-795.
PMID: 35289960
Objective: The objective of this study was to determine the impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to severe acute respiratory...